Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program.

Franco JG Jr, Baruffi RL, Mauri AL, Petersen CG, Chufallo JE, Felipe V, Garbellini E

Journal of assisted reproduction and genetics1 Nov 2001Cited by 9 (Europe PMC)

PMID11804427PMCIDPMC3455697DOI10.1023/a:1013108921427PepBankPUB-11804427

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In ICSI patients, mean oocyte retrieval was 10.5 with nafarelin versus 10.2 with leuprolide, without a significant difference.
In plain wordsIn ICSI patients, mean egg retrieval was 10.5 with nafarelin versus 10.2 with leuprolide, with no significant difference.
Peptide
Nafarelin
Outcome
No significant changeOocytes retrieved
Study
n = 238
Comparator
Leuprolide acetate 0.5 mg subcutaneously once a day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg twice a day · nasal · From menstrual cycle day 21 until the day of HCGAs given in this study (human).
Measurements
Oocytes retrieved
10.5 oocytes
nafarelin, +/- 5.93
Oocytes retrieved
10.2 oocytes
leuprolide, +/- 6.36
P value
0.57
between groups
Source sentences
Summary
The number of oocytes retrieved from Group I (10.5 +/- 5.93) was also similar (p = 0.57) to that retrieved from Group II (10.2 +/- 6.36).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective study was conducted to compare the efficiency of ovarian blockade with nafarelin versus leuprolide in a population whose indication for assisted reproduction was the male factor
Summary · context
A total of 238 patients were assigned at random to two types of treatment: Group I (119 aspirations), nafarelin (Synarel, Searle), 200 microg by the nasal route twice a day, and Group II (119 aspirations), leuprolide acetate (Lupron, Abbott), 0.5 mg by the subcutaneous route once a day.
Summary · context
Both types of blockade were started during the 2nd phase (21st day of the menstrual cycle) and were continued until the day of HCG (5,000-10,000 IU).
Summary · context
All patients received a fixed dose of recombinant FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response.
Report a problemFND-1180442701
02HumanRandomized controlled trialEfficacy outcome
In ICSI patients, mean metaphase II oocyte retrieval was 8.2 with nafarelin versus 7.9 with leuprolide, without a significant difference.
In plain wordsIn ICSI patients, mature egg retrieval averaged 8.2 with nafarelin versus 7.9 with leuprolide, with no significant difference.
Peptide
Nafarelin
Outcome
No significant changeMetaphase II oocytes
Study
n = 238
Comparator
Leuprolide acetate 0.5 mg subcutaneously once a day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg twice a day · nasal · From menstrual cycle day 21 until the day of HCGAs given in this study (human).
Measurements
Metaphase II oocytes
8.2 oocytes
nafarelin, +/- 4.61
Metaphase II oocytes
7.9 oocytes
leuprolide, +/- 5.2
P value
0.58
between groups
Source sentences
Summary
In addition, there was no difference (p = 0.58) in the number of oocytes retrieved at Metaphase II between Group I (8.2 +/- 4.61) and Group II (7.9 +/- 5.2).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective study was conducted to compare the efficiency of ovarian blockade with nafarelin versus leuprolide in a population whose indication for assisted reproduction was the male factor
Summary · context
A total of 238 patients were assigned at random to two types of treatment: Group I (119 aspirations), nafarelin (Synarel, Searle), 200 microg by the nasal route twice a day, and Group II (119 aspirations), leuprolide acetate (Lupron, Abbott), 0.5 mg by the subcutaneous route once a day.
Summary · context
Both types of blockade were started during the 2nd phase (21st day of the menstrual cycle) and were continued until the day of HCG (5,000-10,000 IU).
Summary · context
All patients received a fixed dose of recombinant FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response.
Report a problemFND-1180442702
03HumanRandomized controlled trialEfficacy outcome
In ICSI patients, fertilization rates were 67.5% with nafarelin versus 68.1% with leuprolide, without a significant difference.
In plain wordsIn ICSI patients, fertilization rates were 67.5% with nafarelin versus 68.1% with leuprolide, with no significant difference.
Peptide
Nafarelin
Outcome
No significant changeFertilization rate
Study
n = 238
Comparator
Leuprolide acetate 0.5 mg subcutaneously once a day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg twice a day · nasal · From menstrual cycle day 21 until the day of HCGAs given in this study (human).
Measurements
Fertilization rate
67.5%
nafarelin, +/- 21.3
Fertilization rate
68.1%
leuprolide, +/- 23
P value
0.81
between groups
Source sentences
Summary
Fertilization rates and embryo scores were similar (p = 0.81 and p = 0.25, respectively) for Group I (67.5% +/- 21.3 and 34.4% +/- 14.4) and Group II (68.1% +/- 23and32.2% +/- 14.7, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective study was conducted to compare the efficiency of ovarian blockade with nafarelin versus leuprolide in a population whose indication for assisted reproduction was the male factor
Summary · context
A total of 238 patients were assigned at random to two types of treatment: Group I (119 aspirations), nafarelin (Synarel, Searle), 200 microg by the nasal route twice a day, and Group II (119 aspirations), leuprolide acetate (Lupron, Abbott), 0.5 mg by the subcutaneous route once a day.
Summary · context
Both types of blockade were started during the 2nd phase (21st day of the menstrual cycle) and were continued until the day of HCG (5,000-10,000 IU).
Summary · context
All patients received a fixed dose of recombinant FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response.
Report a problemFND-1180442703
04HumanRandomized controlled trialEfficacy outcome
In ICSI patients, embryo scores were 34.4% with nafarelin versus 32.2% with leuprolide, without a significant difference.
In plain wordsIn ICSI patients, embryo scores were 34.4% with nafarelin versus 32.2% with leuprolide, with no significant difference.
Peptide
Nafarelin
Outcome
No significant changeEmbryo score
Study
n = 238
Comparator
Leuprolide acetate 0.5 mg subcutaneously once a day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg twice a day · nasal · From menstrual cycle day 21 until the day of HCGAs given in this study (human).
Measurements
Embryo score
34.4%
nafarelin, +/- 14.4
Embryo score
32.2%
leuprolide, +/- 14.7
P value
0.25
between groups
Source sentences
Summary
Fertilization rates and embryo scores were similar (p = 0.81 and p = 0.25, respectively) for Group I (67.5% +/- 21.3 and 34.4% +/- 14.4) and Group II (68.1% +/- 23and32.2% +/- 14.7, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective study was conducted to compare the efficiency of ovarian blockade with nafarelin versus leuprolide in a population whose indication for assisted reproduction was the male factor
Summary · context
A total of 238 patients were assigned at random to two types of treatment: Group I (119 aspirations), nafarelin (Synarel, Searle), 200 microg by the nasal route twice a day, and Group II (119 aspirations), leuprolide acetate (Lupron, Abbott), 0.5 mg by the subcutaneous route once a day.
Summary · context
Both types of blockade were started during the 2nd phase (21st day of the menstrual cycle) and were continued until the day of HCG (5,000-10,000 IU).
Summary · context
All patients received a fixed dose of recombinant FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response.
Report a problemFND-1180442704
05HumanRandomized controlled trialEfficacy outcome
In ICSI patients, pregnancy rates per puncture were 30.2% with nafarelin versus 24.4% with leuprolide, without a significant difference.
In plain wordsIn ICSI patients, pregnancy rates per puncture were 30.2% with nafarelin versus 24.4% with leuprolide, with no significant difference.
Peptide
Nafarelin
Outcome
No significant changePregnancy rate per puncture
Study
n = 238
Comparator
Leuprolide acetate 0.5 mg subcutaneously once a day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg twice a day · nasal · From menstrual cycle day 21 until the day of HCGAs given in this study (human).
Measurements
Pregnancy per puncture
30.2%
nafarelin
Pregnancy per puncture
24.4%
leuprolide
P value
0.38
between groups
Source sentences
Summary
Inaddition, pregnancy rates per puncture and per embryo transfer and implantation rates were similar for Group I (30.2, 31.3, and 16.2%, respectively) then compared with Group 11(24.4, 25.2, and 12.6%, respectively) (p = 0.38, p = 0.37, and p = 0.22, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective study was conducted to compare the efficiency of ovarian blockade with nafarelin versus leuprolide in a population whose indication for assisted reproduction was the male factor
Summary · context
A total of 238 patients were assigned at random to two types of treatment: Group I (119 aspirations), nafarelin (Synarel, Searle), 200 microg by the nasal route twice a day, and Group II (119 aspirations), leuprolide acetate (Lupron, Abbott), 0.5 mg by the subcutaneous route once a day.
Summary · context
Both types of blockade were started during the 2nd phase (21st day of the menstrual cycle) and were continued until the day of HCG (5,000-10,000 IU).
Summary · context
All patients received a fixed dose of recombinant FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response.
Report a problemFND-1180442705
06HumanRandomized controlled trialEfficacy outcome
In ICSI patients, pregnancy rates per embryo transfer were 31.3% with nafarelin versus 25.2% with leuprolide, without a significant difference.
In plain wordsIn ICSI patients, pregnancy rates per embryo transfer were 31.3% with nafarelin versus 25.2% with leuprolide, with no significant difference.
Peptide
Nafarelin
Outcome
No significant changePregnancy rate per embryo transfer
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg subcutaneously once a day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg twice a day · nasal · From menstrual cycle day 21 until the day of HCGAs given in this study (human).
Measurements
Pregnancy per embryo transfer
31.3%
nafarelin
Pregnancy per embryo transfer
25.2%
leuprolide
P value
0.37
between groups
Source sentences
Summary
Inaddition, pregnancy rates per puncture and per embryo transfer and implantation rates were similar for Group I (30.2, 31.3, and 16.2%, respectively) then compared with Group 11(24.4, 25.2, and 12.6%, respectively) (p = 0.38, p = 0.37, and p = 0.22, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective study was conducted to compare the efficiency of ovarian blockade with nafarelin versus leuprolide in a population whose indication for assisted reproduction was the male factor
Summary · context
A total of 238 patients were assigned at random to two types of treatment: Group I (119 aspirations), nafarelin (Synarel, Searle), 200 microg by the nasal route twice a day, and Group II (119 aspirations), leuprolide acetate (Lupron, Abbott), 0.5 mg by the subcutaneous route once a day.
Summary · context
Both types of blockade were started during the 2nd phase (21st day of the menstrual cycle) and were continued until the day of HCG (5,000-10,000 IU).
Summary · context
All patients received a fixed dose of recombinant FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response.
Report a problemFND-1180442706
07HumanRandomized controlled trialEfficacy outcome
In ICSI patients, implantation rates were 16.2% with nafarelin versus 12.6% with leuprolide, without a significant difference.
In plain wordsIn ICSI patients, implantation rates were 16.2% with nafarelin versus 12.6% with leuprolide, with no significant difference.
Peptide
Nafarelin
Outcome
No significant changeImplantation rate
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg subcutaneously once a day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 microg twice a day · nasal · From menstrual cycle day 21 until the day of HCGAs given in this study (human).
Measurements
Implantation rate
16.2%
nafarelin
Implantation rate
12.6%
leuprolide
P value
0.22
between groups
Source sentences
Summary
Inaddition, pregnancy rates per puncture and per embryo transfer and implantation rates were similar for Group I (30.2, 31.3, and 16.2%, respectively) then compared with Group 11(24.4, 25.2, and 12.6%, respectively) (p = 0.38, p = 0.37, and p = 0.22, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective study was conducted to compare the efficiency of ovarian blockade with nafarelin versus leuprolide in a population whose indication for assisted reproduction was the male factor
Summary · context
A total of 238 patients were assigned at random to two types of treatment: Group I (119 aspirations), nafarelin (Synarel, Searle), 200 microg by the nasal route twice a day, and Group II (119 aspirations), leuprolide acetate (Lupron, Abbott), 0.5 mg by the subcutaneous route once a day.
Summary · context
Both types of blockade were started during the 2nd phase (21st day of the menstrual cycle) and were continued until the day of HCG (5,000-10,000 IU).
Summary · context
All patients received a fixed dose of recombinant FSH for 7 days and on the 8th day of stimulation the doses started to be adapted according to ovarian response.
Report a problemFND-1180442707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.